10-Q: CV Sciences Narrows Losses, Boosts Cash Flow

CV Sciences, Inc. reported significantly reduced net and operating losses and positive cash flow from operations for the first half of 2025, despite a decline in product sales.

Summary

• Product sales, net, decreased by 8.4% to $3.62 million for the three months ended June 30, 2025, and by 9.2% to $7.23 million for the six months ended June 30, 2025, compared to the prior year periods, primarily due to lower sales volume and average sales price per unit.
• Gross margin improved to 50.9% for the second quarter of 2025 (from 47.0% in Q2 2024) and to 48.5% for the first six months of 2025 (from 46.7% in H1 2024), driven by lower freight costs, reduced inventory losses, and favorable product/channel mix.
• Operating loss significantly narrowed to $(0.13) million for Q2 2025 (from $(0.58) million in Q2 2024) and to $(0.12) million for H1 2025 (from $(1.20) million in H1 2024).
• Net loss substantially decreased to $(0.26) million for Q2 2025 (from $(0.58) million in Q2 2024) and to $(0.37) million for H1 2025 (from $(1.21) million in H1 2024).
• Generated positive cash flow from operations of $0.21 million for the six months ended June 30, 2025, a significant improvement from negative cash flow of $(0.58) million in the prior year period.
• Cash balance increased to $0.89 million as of June 30, 2025, from $0.45 million at December 31, 2024.
• Recognized a $0.5 million benefit from the reversal of accrued payroll taxes in the first half of 2025 due to the expiration of the statute of limitations related to a former CEO's RSU settlement.
• Recognized a $37,500 gain on the extinguishment of the Streeterville Note, which was fully repaid prior to its maturity date.
• Received net proceeds of $1.2 million in February 2025 from a new secured promissory note with an institutional investor.
• Management continues to express substantial doubt about the company's ability to continue as a going concern, citing an accumulated deficit of $87.4 million as of June 30, 2025, and ongoing dependence on additional investment capital.

Sentiment

Score: 6

Explanation: The company demonstrated significant improvements in reducing net and operating losses and achieved positive cash flow from operations, indicating better financial management and efficiency. However, these positives are tempered by declining product sales, ongoing substantial doubt about the company's ability to continue as a going concern, and a highly uncertain and competitive regulatory environment for its core CBD products. The legal dispute with former counsel adds another layer of uncertainty.

Positives

• Net loss significantly reduced to $(0.37) million for the six months ended June 30, 2025, from $(1.21) million in the prior year period, demonstrating improved financial performance.
• Operating loss substantially narrowed to $(0.12) million for the six months ended June 30, 2025, from $(1.20) million in the prior year period, reflecting better operational efficiency.
• Gross margin improved to 48.5% for the first six months of 2025, up from 46.7% in the same period last year, due to lower freight costs, reduced inventory losses, and favorable product mix.
• Achieved positive cash flow from operations of $0.21 million for the six months ended June 30, 2025, a significant turnaround from negative cash flow of $(0.58) million in the prior year.
• Cash balance increased to $0.89 million as of June 30, 2025, from $0.45 million at the end of 2024.
• Realized a $0.5 million benefit from the reversal of accrued payroll taxes due to the expiration of the statute of limitations, improving the balance sheet.
• Recognized a $37,500 gain on the early extinguishment of the Streeterville Note, demonstrating effective debt management.
• Successfully secured $1.2 million in net proceeds from a new secured promissory note in February 2025, enhancing liquidity.

Negatives

• Product sales, net, decreased by 9.2% to $7.23 million for the six months ended June 30, 2025, compared to $7.96 million in the prior year period, primarily due to lower sales volume and average sales price per unit.
• The company continues to have an accumulated deficit of $87.4 million as of June 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• Management anticipates continued dependence on additional investment capital to fund operations and growth initiatives for the near future.
• The overall market for hemp-based CBD products remains fragmented and highly competitive, exacerbated by a lack of clear federal regulatory framework and evolving state regulations.
• A California emergency order banning certain hemp products has negatively impacted operating results and is expected to continue to do so.
• An ongoing arbitration with former legal counsel Procopio seeks to recover damages from alleged incorrect tax advice, adding legal uncertainty and potential costs.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to accumulated deficit and reliance on additional investment capital.
• Intense competition from both licensed and illicit market operators in the herbal supplements and hemp-based CBD consumer products market.
• Lack of a clear federal regulatory framework for CBD products, leading to a fragmented and constantly evolving patchwork of state regulations.
• Adverse impact on sales and operations from restrictive state regulations, such as the California emergency order banning certain hemp products.
• Uncertainty and differing interpretations among federal, state, and local regulatory agencies regarding the regulation of cannabinoids, including FDA's stance on CBD in dietary supplements and conventional foods.
• Potential adverse effects from changes in U.S. and foreign government trade policies, including increased tariffs on imports from China, which could force price increases or operational changes.
• General economic or consumer trends, including constrained global economic conditions, rising inflation, and high Federal Reserve interest rates, could adversely impact business and financial performance.
• Potential for reductions in business activity, increased funding costs, decreased share price, and lower profitability if current levels of market disruption and volatility continue.
• Risk of not being successful in capital-raising efforts, which could adversely affect future operations and viability.
• Ongoing legal proceedings, including a class action lawsuit regarding product labeling and an arbitration with former legal counsel, could result in significant costs or adverse outcomes.

Future Outlook

The company intends to continue innovating new products, building brand awareness, and making significant investments in its business strategy, including introducing new products, adopting quality assurance protocols, and expanding market presence. It plans to undertake further research and development and pursue additional acquisitions to diversify product offerings. Management anticipates continued dependence on additional investment capital to fund operations and growth initiatives and will continue to implement strategic cost reductions, including reductions in employee headcount and vendor spending, and delaying expenses related to its drug development activities. The company aims to raise additional funds through capital markets, debt issuance, and/or securing lines of credit. The California emergency order banning certain hemp products is expected to continue to negatively impact the business.

Management Comments

• "Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operations, growth initiatives and will continue to make and implement strategic cost reductions, including reductions in employee headcount, vendor spending, and delaying expenses related to its drug development activities."
• "The Company intends to position itself so that it will be able to raise additional funds through the capital markets, issuance of debt, and/or securing lines of credit."
• "The overall market continues to be fragmented and highly competitive, which we believe is largely due to the lack of a clear regulatory framework and a patchwork of state regulation."

Industry Context

The company operates in the consumer wellness market, focusing on hemp extracts (CBD) and plant-based food products. This market is characterized by intense competition and fragmentation, largely due to the absence of a clear federal regulatory framework for CBD and a complex, evolving landscape of state-specific regulations. The company's strategy of acquiring Cultured Foods (plant-based protein) and Elevated Softgels (encapsulated softgels/tinctures) reflects a broader industry trend towards diversification and vertical integration to build more efficient consumer product platforms. The pursuit of a drug development program for CBD-based therapeutics indicates a potential strategic shift or expansion into the pharmaceutical sector, which is a distinct but related industry segment. The mention of industry consolidation during economic downturns suggests the company is navigating a dynamic environment where larger players or more diversified entities may emerge.

Comparison to Industry Standards

• The company's +PlusCBD branded products are cited as top-selling brands of hemp extracts in the natural products market, according to SPINS, a leading data provider for the natural, organic, and specialty products industry. However, specific market share data or direct comparisons to competitors' financial performance are not provided.
• The gross margin improvement to 48.5% for the first six months of 2025 is a positive indicator of cost management within a competitive industry, though without specific industry benchmarks, it's difficult to assess its relative strength.
• The market is described as fragmented and highly competitive due to regulatory uncertainty, which is a common characteristic of the nascent and evolving CBD industry in the U.S. and globally.

Corporate Governance

Legal Proceedings

• **Ruth Complaint (Shareholder Derivative Suit)**: Alleging breach of fiduciary duty and gross mismanagement. A settlement in principle was agreed upon in January 2022, including corporate governance reforms. Preliminary approval was granted on February 7, 2023. The court granted plaintiff's attorney's fees and expenses of approximately $250,000 on May 23, 2023, with a stipulation for payment over approximately eighteen months executed around May 1, 2024.
• **Colette Complaint (Putative Class Action)**: Alleging product labeling violated the Food, Drug, and Cosmetic Act of 1938. The proceeding was stayed by court order on May 22, 2020, pending FDA rulemaking regarding CBD ingestible products. Despite the FDA's announcement on January 26, 2023, that it does not intend to pursue such rulemaking, the case remains stayed.
• **Arbitration with Procopio (Former Legal Counsel)**: Initiated on February 12, 2025, asserting claims against Procopio for damages resulting from alleged incorrect legal advice regarding tax withholding on former CEO Michael Mona Jr.'s RSU settlement. Procopio terminated the company as a client on January 10, 2025. The arbitration hearing is scheduled to begin on May 18, 2026.

Related Party Transactions

• **Michael Mona Jr. (Former President and Chief Executive Officer)**: In 2019, a Settlement Agreement was reached regarding his resignation, stock options, and RSU settlement. The company recorded significant stock-based compensation expense related to this. A contingent liability of $6.2 million for income taxes and $0.5 million for FICA taxes related to Mona's RSU settlement (where no amounts were withheld) was derecognized in Q1 2023 and H1 2025, respectively, due to the expiration of statutes of limitations. Mona confirmed he has not paid his personal income tax for 2019. A case brought by Mona against the company was resolved in the company's favor in binding arbitration in November 2024.

Stakeholder Impact

• **Shareholders**: Face potential dilution from future capital raises, uncertainty due to the 'going concern' doubt, and volatility from the declining sales and regulatory risks. However, improved financial performance (reduced losses, positive cash flow) could positively impact sentiment.
• **Employees**: Subject to strategic cost reductions, including potential reductions in employee headcount.
• **Customers**: May experience impacts from the California emergency order affecting product availability and potential price adjustments due to tariffs.
• **Suppliers/Vendors**: May be affected by strategic cost reductions, including reductions in vendor spending.
• **Creditors**: The company has secured new debt financing ($1.2 million) and successfully repaid the Streeterville Note, which could be viewed positively by current and potential creditors, but the 'going concern' doubt remains a concern.

Next Steps

• Continue to innovate new products and build brand awareness.
• Make significant investments in business strategy by introducing new products and building market presence.
• Adopt quality assurance protocols and procedures.
• Undertake further research and development.
• Make additional acquisitions to further diversify product offerings.
• Continue to make and implement strategic cost reductions, including reductions in employee headcount and vendor spending.
• Delay certain expenses related to drug development activities.
• Work towards increasing revenue and operating cash flows to meet future liquidity requirements.
• Evaluate options related to the purported termination of the Extract Labs Purchase Agreement.
• Proceed with the arbitration hearing against Procopio, scheduled to begin on May 18, 2026.

Key Dates

Recommendation

While CV Sciences demonstrated significant improvements in reducing net and operating losses and achieved positive cash flow from operations for the first half of 2025, indicating better cost management and efficiency, the company continues to operate under substantial doubt about its ability to continue as a going concern. Product sales are declining, and the regulatory landscape for CBD products remains highly uncertain and competitive, particularly with the extended California emergency order. The ongoing legal dispute with former counsel adds further complexity. These factors present considerable risks that temper the positive financial trends, suggesting a 'hold' position until there is clearer resolution on liquidity, sustained revenue growth, and regulatory clarity.

Keywords

CV Sciences, Hemp, CBD, Nutraceuticals, Plant-based foods, Financial results, Quarterly report, SEC filing, Cannabis industry, Consumer wellness, Going concern, Regulatory risk, Liquidity